Publications by authors named "D Desaiah"

Claim this Profile
P
Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor.
Jonathan M Yingling, William T McMillen, Lei Yan, Huocong Huang, J Scott Sawyer, Durisala Desaiah

Oncotarget· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
David Capper, Andreas von Deimling, Alba A Brandes, Antoine F Carpentier, Santosh Kesari, Durisala Desaiah

Int J Mol Sci· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer.
Ivelina Gueorguieva, Ann Cleverly, Durisala Desaiah, Analia Azaro, Joan Seoane

Drugs Context· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.
Alba A Brandes, Antoine F Carpentier, Santosh Kesari, Juan M Sepulveda-Sanchez, Helen R Wheeler, Durisala Desaiah

Neuro Oncol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.
Stephan Herbertz, J Scott Sawyer, Anja J Stauber, Ivelina Gueorguieva, Kyla E Driscoll, Durisala Desaiah

Drug Des Devel Ther· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis